Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Travere Therapeutics Q2 2024 Adj. EPS $(0.65) Beats $(0.86) Estimate, Sales $52.176M Beat $50.169M Estimate

Author: Benzinga Newsdesk | August 01, 2024 04:49pm
Travere Therapeutics (NASDAQ:TVTX) reported quarterly losses of $(0.65) per share which beat the analyst consensus estimate of $(0.86) by 24.42 percent. This is a 17.72 percent increase over losses of $(0.79) per share from the same period last year. The company reported quarterly sales of $52.176 million which beat the analyst consensus estimate of $50.169 million by 4.00 percent. This is a 12.60 percent decrease over sales of $59.697 million the same period last year.

Posted In: TVTX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist